Movember Foundation
Movember Foundation
Explore linked clinical trials.6 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The PROSECCA Study, Answering New Questions in Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Not stated | 2026-08-26 | NCT06714630 | |
| Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors | Female Urogenital Diseases and Pregnancy Complications, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Nonseminomatous germ cell tumor, Pregnancy Complications, Neoplastic, Urogenital Diseases, adenocarcinoma, carcinoma, choriocarcinoma, epithelial neoplasm, extragonadal seminoma, germinoma, malignant germ cell tumor, mesonephric neoplasm, mixed germ cell tumor, neoplasm, nongerminomatous germ cell tumor, pregnancy disorder, seminoma, teratoma, trophoblastic neoplasm, yolk sac tumor | Active, not recruiting | Phase 3 | 2026-06-16 | NCT02375204 | |
| Prostate Cancer Awareness and Initiative for Screening in the European Union | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Enrolling by invitation | Not stated | 2025-08-15 | NCT06424275 | |
| In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy | Metastatic Hormone Naive Prostate Cancer | Active, not recruiting | Phase 2 | 2025-07-11 | NCT04343885 | |
| INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4) | Genital Diseases, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Not applicable | 2024-11-27 | NCT02730338 | |
| Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 1 / Phase 2 | 2024-11-08 | NCT04430192 |